Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06825715 · ClinicalTrials.gov registry record · NA

Multilevel Intervention for Precision Oncology

A NA study of Advanced Cancers of the Prostate and Cancers of the Lung, sponsored by VA Office of Research and Development.

Recruiting
Registry status
NA
Development phase
2,653
Enrollment target
1
Study location

NCT06825715: Recruiting NA study of Advanced Cancers of the Prostate and Cancers of the Lung, sponsored by VA Office of Research and Development.

NCT06825715 is a NA study of Advanced Cancers of the Prostate and Cancers of the Lung that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 2,653 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06825715, a NA study of Advanced Cancers of the Prostate and Cancers of the Lung, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
NA
Development phase
2,653 participants
Enrollment target
1
Study location

Study Summary

The investigators are rolling out a 3 level intervention designed to improve the use of Precision Oncology at 8 VA medical centers. The 3 components of the intervention are 1: a short educational video for patients, 2: audit and feedback to providers on their Precision Oncology practice patterns, and 3: a change in the electronic medical record to make it easier to order and review results of Precision Oncology tests.

Primary Outcome

Proportion of eligible patients with lung and prostate cancer who have next generation sequencing molecular testing

Interventions

  • OTHER Multilevel intervention

Study Locations (1)

New York

  • VA NY Harbor Healthcare System, New York, NY - New York

Trial Details

FieldValue
Enrollment Target 2,653 participants
Start Date 2025-07-02
Est. Completion 2030-02-28
Phase NA
VA Office of Research and Development

1,668 total trials

What NCT06825715 shows while recruiting

NCT06825715 is an interventional study that assigns participants to a tested intervention. Its 2,653 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% higher).

The record links to 2 conditions, with Advanced Cancers of the Prostate appearing as the primary indexed condition, and to 1 intervention - of which Multilevel intervention is the first listed.

NCT06825715 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06825715 about?

NCT06825715 is a clinical study titled "Multilevel Intervention for Precision Oncology". The investigators are rolling out a 3 level intervention designed to improve the use of Precision Oncology at 8 VA medical centers. The 3 components of the intervention are 1: a short educational video for patients, 2: audit and feedback to providers on their Precision Oncology practice patterns, an...

What is the current status of trial NCT06825715?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,653 participants. The study started on 2025-07-02. Estimated completion is 2030-02-28.

What conditions does trial NCT06825715 study?

This clinical trial studies the following conditions: Advanced Cancers of the Prostate, Cancers of the Lung.

What interventions are being tested in trial NCT06825715?

The interventions under investigation include: Multilevel intervention (OTHER).

Who is sponsoring clinical trial NCT06825715?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06825715 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT06825715's enrollment target sits among peer trials

2,653 44th of 2000 higher than 1,957 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06455085 · 2,634 participants · NA

    RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

  • NCT05471908 · 2,674 participants · NA

    Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

  • NCT05111925 · 2,690 participants

    Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement

  • NCT04073420 · 2,700 participants

    Medtronic Cardiac Surgery PMCF Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06825715, the US trial registry maintained by the National Library of Medicine. NCT06825715 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.